Search…

Novartis Pharmaceuticals (NVS.US) acquires Tourmaline Bio (TRML.US) at $48 per share, doubling down on cardiovascular disease therapy.

09/09/2025

According to the China Fortune Financial APP, Swiss pharmaceutical giant Novartis (NVS.US) announced on Tuesday that it will acquire American biopharmaceutical company Tourmaline Bio (TRML.US) at a price of $48 per share. The valuation of Tourmaline Bio in this transaction is $1.4 billion. In response to this news, Tourmaline Bio's US stock rose nearly 13% on Tuesday.

Latest

1 m ago

Vietnam approves a five-year pilot of encrypted transactions, allowing only local companies to settle in Vietnamese dong.

1 m ago

Source: The Italian government still expects the economic growth rate to be 0.6% in 2025. Italy's interest savings are assumed to be 5 billion euros in 2025 and 8 billion euros in 2026.

2 m ago

The chief financial officer of Wealth Bank said that since the removal of the asset cap, we have found that customers are more willing to do business with us.

2 m ago

The chief financial officer of Bank of Wealth stated that since the removal of the asset cap, we have found that customers are more willing to do business with us.

2 m ago

Lantu automobile: Lanhai IntelliMix 5C fast charge can reach 80% from 20% in just 12 minutes! It has successfully passed various rigorous tests such as continuous washing for 8 hours in dust mode, corrosion in salt spray for 720 hours, and 38000N bottom ball impact.

See all latest